此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth

2017年8月1日 更新者:St. Renatus, LLC

A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults

The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and Placebo for inducing pulpal anesthesia of the maxillary teeth in adults.

研究概览

详细说明

The study will employ a multi-center, randomized, double-blind, placebo-controlled, parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary right second premolar to maxillary left second premolar) sufficient to allow completion of the Study Dental Procedure.

A total of 140 subjects, randomized 2:2:1 (Kovacaine Mist:Tetracaine alone:Placebo) will be enrolled to achieve 125 completed subjects; a total of 50 Kovacaine Mist subjects, 50 tetracaine alone subjects and 25 placebo subjects. Recruitment will be from diverse dental patient populations. At the two study sites, a balanced enrollment of 70 subjects each is planned to allow for a potential 10% drop-out rate.

研究类型

介入性

注册 (实际的)

26

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Baltimore、Maryland、美国、20740
        • University of Maryland, Baltimore
    • Utah
      • Salt Lake City、Utah、美国、84124
        • Jean Brown Research
      • Salt Lake City、Utah、美国、84124
        • Family and Cosmetic Dentistry

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female 18 years of age or older.
  • Need for an operative restorative dental procedure requiring local anesthesia for a single vital maxillary tooth (other than a maxillary first, second, or third molar) with no evidence of pulpal pathology.
  • Normal lip, nose, eyelid, and cheek sensation.
  • Able to understand and sign the study informed consent document, communicate with the investigators, and understand and comply with the requirements of the protocol.
  • Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.
  • Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.
  • Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.

Exclusion Criteria:

  • Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).
  • Inadequately controlled active thyroid disease of any type.
  • Frequent nose bleeds (≥ 5 per month).
  • Having received dental care requiring a local anesthetic within the last 24 hours.
  • History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).
  • History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite preservatives.
  • Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.
  • Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females of child-bearing potential will be required to take a urine pregnancy test on the day of, but prior to, study drug administration to rule out pregnancy.)
  • Having received any investigational drug and/or participation in any clinical trial within 30 days prior to study participation.
  • Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other nasal or oral decongestant on the day of the study procedure.
  • History of congenital or idiopathic methemoglobinemia

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Kovacaine Mist, 3 sprays unilateral
Tetracaine HCl 3% and oxymetazoline HCl 0.05%
3 unilateral intranasal sprays per dose
其他名称:
  • 可伐卡因喷雾
实验性的:Tetracaine Only, 3 sprays unilateral
Tetracaine HCl 3%
每剂量 3 次单侧鼻内喷雾
安慰剂比较:Placebo, 3 sprays unilateral
Placebo
每剂量 3 次单侧鼻内喷雾

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).
大体时间:at 15 minutes with a 3 minute window
at 15 minutes with a 3 minute window

次要结果测量

结果测量
措施说明
大体时间
Intraoral Soft-tissue Anesthesia (Yes/no)
大体时间:at 15 minutes with a 3 minute window
Number of patients who reported no pain when incisive papilla and greater palatine foramen soft-tissue was tested with a probe
at 15 minutes with a 3 minute window
Number of Participants With Heart Rate Higher Than 125 Bpm
大体时间:at any time within 120 minutes following drug administration
at any time within 120 minutes following drug administration
Number of Participants With Heart Rate Lower Than 50 Bpm
大体时间:at any time within 120 minutes following drug administration
at any time within 120 minutes following drug administration
收缩压从基线增加到大于或等于 25 毫米汞柱且值高于 160 毫米汞柱的参与者人数
大体时间:给药后 120 分钟内的任何时间
给药后 120 分钟内的任何时间
收缩压从基线下降大于或等于 15 毫米汞柱且值低于 90 毫米汞柱的参与者人数
大体时间:给药后 120 分钟内的任何时间
给药后 120 分钟内的任何时间
Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg
大体时间:at any time within 120 minutes following drug administration
at any time within 120 minutes following drug administration
Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
大体时间:at any time within 120 minutes following drug administration
at any time within 120 minutes following drug administration
Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
大体时间:from baseline to 120 minutes following drug administration
from baseline to 120 minutes following drug administration
心率随时间的变化
大体时间:从基线到给药后 120 分钟
从基线到给药后 120 分钟
Alcohol Sniff Test
大体时间:administered at approximately 24 hours after drug administration
The change from screening in the the distance from the nose (in centimeters) that a patient is able to detect the smell of an alcohol swab.
administered at approximately 24 hours after drug administration
收缩压随时间变化的曲线
大体时间:从基线到给药后 120 分钟
从基线到给药后 120 分钟
舒张压随时间变化的曲线
大体时间:从基线到给药后 120 分钟
从基线到给药后 120 分钟
心率相对于基线的绝对最大变化
大体时间:从基线到给药后 120 分钟
从基线到给药后 120 分钟

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年8月1日

初级完成 (实际的)

2012年9月1日

研究完成 (实际的)

2012年9月1日

研究注册日期

首次提交

2012年8月2日

首先提交符合 QC 标准的

2012年8月8日

首次发布 (估计)

2012年8月9日

研究记录更新

最后更新发布 (实际的)

2017年9月5日

上次提交的符合 QC 标准的更新

2017年8月1日

最后验证

2017年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅